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Recent studies have revealed that the human and nonrodent mammalian airway mucosa contains an oxidative
host defense system. This three-component system consists of the hydrogen peroxide (H2O2)-producing
enzymes dual oxidase (Duox)1 and Duox2, thiocyanate (SCN−), and secreted lactoperoxidase (LPO). The
LPO-catalyzed reaction between H2O2 and SCN− yields the bactericidal hypothiocyanite (OSCN−) in
airway surface liquid (ASL). Although SCN− is the physiological substrate of LPO, the Duox/LPO/halide
system can generate hypoiodous acid when the iodide (I−) concentration is elevated in ASL. Because
hypoiodous acid, but not OSCN−, inactivates respiratory syncytial virus (RSV) in cell culture, we used a lamb
model of RSV to test whether potassium iodide (KI) could enhance this system in vivo. Newborn lambs
received KI by intragastric gavage or were left untreated before intratracheal inoculation of RSV. KI treatment
led to a 10-fold increase in ASL I− concentration, and this I− concentration was approximately 30-fold higher
than that measured in the serum. Also, expiratory effort, gross lung lesions, and pulmonary expression of an
RSV antigen and IL-8 were reduced in the KI-treated lambs as compared with nontreated control lambs.
Inhibition of LPO activity significantly increased lesions, RSV mRNA, and antigen. Similar experiments in
3-week-old lambs demonstrated that KI administration was associated with reduced gross lesions, decreased
RSV titers in bronchoalveolar lavage fluid, and reduced RSV antigen expression. Overall, these data indicate
that high-dose KI supplementation can be used in vivo to lessen the severity of RSV infections, potentially
through the augmentation of mucosal oxidative defenses.
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ABSTRACT 
 
Recent studies have revealed that the human and non-rodent mammalian airway mucosa contains an oxidative 
host defense system.  This three-component system consists of hydrogen peroxide (H2O2)-producing enzymes 
dual oxidase (Duox) 1 and 2, thiocyanate (SCN-), and secreted lactoperoxidase (LPO).  The LPO-catalyzed 
reaction between H2O2 and SCN- yields the bactericidal hypothiocyanite (OSCN-) in airway surface liquid (ASL).  
Although SCN- is the physiological substrate of LPO, the Duox/LPO/halide system can also generate hypoiodous 
acid (HOI) when the iodide (I-) concentration is elevated in ASL.  Since HOI, but not OSCN-, inactivates 
respiratory syncytial virus (RSV) in cell culture, we used a lamb model of RSV to test whether potassium iodide 
(KI) could enhance this system in vivo.  Newborn lambs received KI by intragastric gavage or were left untreated 
prior to the intratracheal inoculation of RSV.  The KI treatment led to a 10-fold increase in ASL I- concentration, 
and this I- concentration was ~30-fold higher than that measured in the serum.  Also, expiratory effort, gross lung 
lesions, and pulmonary expression of an RSV antigen and interleukin-8 were reduced in the KI-treated lambs as 
compared to non-treated controls.  Inhibition of LPO significantly increased lesions, and RSV mRNA and antigen.  
Similar experiments in 3-week-old lambs also demonstrated that KI administration was associated with reduced 
gross lesions, decreased RSV titers in bronchoalveolar lavage fluid, and reduced RSV antigen expression.  
Overall these data indicate that high-dose KI supplementation can be used in vivo to lessen the severity of RSV 
infections, potentially through the augmentation of mucosal oxidative defenses. 
 
 
Keywords:  mucosal immunity; oxidative defense system; Duox; lactoperoxidase; thiocyanate; airway surface 
liquid; respiratory syncytial virus; potassium iodide; ovine model  
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INTRODUCTION 
Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infection in infants and young 
children and is a leading cause of infantile bronchiolitis worldwide (1, 2).  In industrialized countries, hRSV 
accounts for up to 70% of hospitalized bronchiolitis cases (1-3).  Although the antiviral drugs Palivizumab and 
Ribavirin have virucidal activity against RSV in vivo, there are no fully satisfactory therapeutic regimens or 
vaccines (4-6).  It is estimated that 3% of RSV cases in the United States and 10% of cases worldwide result in 
hospitalization; the reported number of new cases of lower respiratory infection due to RSV in children under 5 
in 2005 was 33.8 million (7, 8).  Thus, there is a need for new therapies for RSV infection. 
 
The host defense activity of the airway epithelium is critical for the continuous inactivation and removal of inhaled 
microbes from the respiratory tract. While the role of mucociliary clearance and epithelial host defense proteins 
and peptides in lung immunity is well established, the recognition that airway epithelial cells express an oxidative 
microbicidal system is recent (9-13; reviewed in 11, 12).  This three-component oxidative system consists of two 
H2O2-generating enzymes of airway epithelia, dual oxidase (Duox) 1 and 2, along with a pseudohalide anion 
(thiocyanate, SCN-), and the enzyme lactoperoxidase (LPO).  The Duox enzymes generate H2O2 into the apical 
extracellular space where H2O2 reacts with secreted SCN- in a LPO-catalyzed reaction to form the antibacterial 
hypothiocyanite (OSCN-) molecule; (H2O2 + SCN- → OSCN-) (10, 13-21).  Both LPO and SCN- are highly 
concentrated in the airway surface liquid (ASL).  The Duox/LPO/SCN- system generates sufficient OSCN- to 
eliminate bacteria in vitro and in vivo (13, 22, 23).  In vitro, the substitution of iodide (I-) for SCN- in this system 
yields hypoiodous acid (H2O2 + I- → HOI) instead of the physiological product, OSCN- (24).  HOI has potent 
microbicidal activity against bacteria (23) and viruses (26), including activity against RSV, whereas OSCN- 
exhibits little antiviral activity (24).  We previously reported that I- is concentrated in the nasal ASL of human 
subjects following oral I- supplementation using an FDA-approved formulation (24).  However, it was not tested 
whether I- supplementation also led to high I- concentration in the ASL of lower airways and whether a high I- 
concentration in the ASL could affect the severity of respiratory viral infections.  
 
The ovine respiratory tract functionally expresses the Duox/LPO/halide system (23), is susceptible to human 
strains of RSV, and develops microscopic lesions similar to those in infants (for review see 27; 28-30).  Some 
other animal species used to model RSV infection (e.g., mice and rats) lack airway submucosal glands (31) 
which are the LPO-secreting structures in the airways of larger mammals.  Without LPO production in the 
airways, the Duox/LPO/halide system is not fully functional.  Therefore, lambs were used to test the hypothesis 
that I- supplementation can protect the newborn lung against RSV infection.  The life cycle of RSV is restricted 
to the epithelia of the respiratory tract.  Because the Duox/LPO/halide system is dependent upon mature epithelia 
and submucosal glands that can produce adequate levels of enzymes and halide transport proteins, studies 
were completed in both newborn and 3-week-old lambs. 
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MATERIALS AND METHODS 
I- concentration measurements in airway secretions and serum.  
The concentrations of I- and SCN- in the nasal secretions and serum of lambs were measured after the 
administration of NaI (1.7 mg/kg body weight, n = 5) or PBS (control, n = 5) via the external jugular vein.  Nasal 
secretions and blood samples were collected at 4 time points: at 0 hour (just before the injection of NaI), 4 h, 12 
h, and 36 h.  Blood (8 ml) was drawn from the external jugular vein, and serum was collected.  Nasal secretions 
were collect with microsampling probes (Olympus BC-402C) as previously described (24, 32).  Nasal fluid was 
recovered from the microsampling probes by microcentrifugation.  Both serum samples and nasal secretions 
were diluted in water and analyzed for anion composition using ion-exchange chromatography as described 
previously (24, 32).  
 
The above described experimental design was slightly modified to determine the effect of intragastric delivery of 
KI on the concentrations of I- and SCN- in airway secretions.  Briefly, lambs (n = 5) received KI-containing PBS 
(1.8 mg KI/kg body weight) via an 18 French Foley catheter followed by 6 ml of water flush to clear.  Nasal 
secretions and serum samples were collected at 0 hour (just before the intragastric gavage), 4 h, 12 h, and 36 
h. At 4 and 12 hour, one animal/time point was euthanized after the collection of serum and nasal secretions to 
harvest tracheobronchial secretions as previously described (24, 32).  The remaining 3 animals were euthanized 
at 36 hours for the collection of tracheobronchial secretions. 
 
Lamb RSV challenge experiments.  
Lambs were randomly assigned to 3 groups: the first group was inoculated with RSV, the second group was 
inoculated with RSV and treated with KI, and the third group was neither inoculated with RSV nor treated with 
KI.  Using this experimental design, a pilot experiment was carried out in which the human pathogen RSV strain 
A2 was delivered through a fiberoptic bronchoscope (108 PFU RSV in 10 ml cell culture medium) into the trachea 
of newborn lambs (2-3 days of age; n = 5).  In this pilot experiment, the KI-treated lambs (n = 5) received 1.8 mg 
KI/kg body weight in PBS by intragastric gavage 4 hours prior to the inoculation of RSV A2 and daily thereafter.  
Control lambs (n = 3) received I- free PBS through via intragastric gavage and sterile cell culture medium (10 ml) 
through the bronchoscope.  In subsequent experiments involving 2-3 day old lambs and 3-week-old lambs, a 
more pathogenic RSV strain (Memphis 37) (27) was delivered (3.5 x 107 PFU) to lambs in 6 ml culture medium 
using a PARI SprintTM nebulizer and a cone face mask fitted with a rubber gasket that provided a seal around 
the mandible and nose.  In addition, the dose of KI was increased to 10 mg KI/kg body weight/day.  Control 
lambs received I- free PBS intragastrically(6 ml) via nebulization and additional group of lambs received Dapsone 
which inhibits lactoperoxidase activity. See online data supplement for additional methods. 
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RESULTS 
Airway surface liquid iodide levels after intravenous and intragastric iodide delivery. 
 
To evaluate the extent to which systemic I- administration to lambs affects the ASL concentration of I-, nasal 
secretions and serum samples were collected from lambs that received sodium iodide (NaI) in PBS intravenously 
(1.7 mg NaI/kg body weight) or PBS only (negative control). Ion-exchange chromatography analysis of these 
samples showed that the I- concentration increased in the nasal secretions to ~340 µM at the 4-hour time point, 
whereas the serum I- concentration only increased to ~14 µM (Figure 1A and 1B).  By the 36-hour time point, 
the I- concentration in the nasal secretions returned to near base-line levels.  Interestingly, the SCN- 
concentration decreased in the nasal secretions when the I- concentration reached its peak in the serum 
(supplemental figure E2), suggesting that SCN- and I- compete for the same transporters in the airway.  I- 
administration to humans also leads to a greatly increased [I-] in the nasal ASL (24).  Thus, our data indicate that 
the upper airway of lambs recapitulates the halide-transporting activity of the human nasal mucosa.  
 
Next, we examined whether intragastric administration of I- also leads to elevated concentration of I- in the 
secretions of the upper and lower airways. We used intragastric gavage to deliver KI (1.8 mg KI/kg body weight) 
to lambs.  Nasal secretions and serum samples were harvested at 4 time points (0, 4, 12 and 36 hours).  
Tracheobronchial secretions were collected immediately after euthanizing lambs at 4, 12, and 36 hours.  Analysis 
of these samples showed that intragastric KI administration led to a more prolonged increase of I- in the serum, 
nasal secretions, and tracheobronchial secretions than the IV delivery of NaI (Figure 1).  Furthermore, the upper 
and lower airway secretions contained similar levels of I- at each time point (Figure 1C).  These data indicate 
that intragastric delivery of I- to lambs leads to elevated I- concentration in the ASL of both the lower and upper 
airways. 
 
Pilot study:  Iodide effects human RSV strain A2 in vivo.   
 
A pilot study was completed in order to establish an initial proof-of-principal that I- would have some effect on 
reducing RSV replication.  Lambs received intragastric KI supplementation or control (i.e. I- free) solution 4 hours 
prior to intratracheal inoculation of hRSV A2 and daily thereafter. The severity of hRSV A2 infection was 
evaluated 6 days later when the RSV-induced lung lesions are maximal in this model (25, 30-33).  In the lungs 
of KI-treated lambs, we found reduced hRSV A2 RNA levels (Figure 2A) and a reduction in gross and histological 
lesions (consolidation score: 2.22 ± 0.9) compared to untreated lambs infected with hRSV A2 (consolidation 
score: 4.9 ± 0.8) (p<0.05).  After 6 days of I- supplementation, treated lambs had significantly increased [I-] in 
tracheal ASL compared to non-supplemented controls (Figure 2B).  These findings suggest that I- administration 
is associated with reduced RSV disease severity. 
 
Iodide effects on RSV M37 infection in newborn (2-3 day-old) lambs. 
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Because the pilot studies demonstrated reductions in both lung lesions and RSV RNA levels, additional 
studies were completed in 2-3 day-old lambs in order to further investigate the extent to which I- reduces RSV 
severity in newborn lambs.  The virus strain RSV Memphis 37 (M37) was used in these studies because M37 is 
less laboratory-adapted than RSV A2 and the lung disease caused by M37 is very similar in lambs and human 
infants. 
 
Effect of KI on clinical parameters, lesions, and bronchoalveolar lavage fluid.  There was a significant reduction 
in the incidence and severity of enhanced expiratory effort (forced expiration) in lambs receiving KI treatment at 
days 2, 3, 4, 5 and 6 post-inoculation (Figure 3A) compared to RSV-inoculated lambs without KI prophylaxis.  
Control lambs showed no increased expiratory effort.  Among virus-treated lambs, 2/12 KI-treated RSV-
inoculated lambs exhibited mildly increased expiratory effort whereas 9/12 lambs given RSV without KI treatment 
had increased expiratory effort that was moderate to marked.  There were no significant differences between 
groups of lambs (RSV M37 without KI treatment; RSV M37 with KI treatment; control) in weight gain, 
temperature, or respiratory rate.  Lung lesions were significantly reduced in KI treated lambs compared to 
untreated RSV-inoculated lambs (Figure 3B).  Gross lesions were present in 11/12 of lambs receiving RSV M37 
without KI; these were marked in 7/12 and mild in 4/12.  In contrast, 2/12 KI-treated lambs receiving RSV M37 
had marked gross lesions, 9/12 had mild lesions, and 1/12 had no lesions.  To evaluate the effect of KI treatment 
on the inflammatory cell populations within the lung, BALF differential cell counts were performed.  In newborn 
lambs, no statistically significant differences were detected between groups.  However, there was a trend for the 
RSV-infected lambs that received KI treatment to have an increased proportion of lymphocytes (p = 0.096; 
ANOVA).  Consolidation scores determined by histopathology for lambs inoculated with RSV M37 lacking KI 
treatment (0.64 ± 0.32) were not significantly altered from lambs treated with KI (0.70 ± 0.29); controls (no RSV; 
no KI) lacked lesions (0.00 consolidation score).  Lambs receiving Dapsone, KI and RSV had significantly 
increased levels of expiratory effort, gross and histologic lesion scores compared to control and KI-treated lambs 
(no Dapsone) and increased gross and microscopic lesions compared to M37 alone (no KI or Dapsone) (Fig. 
3A-D).  The findings, demonstrate that KI treatment reduces some, but not all clinical parameters of RSV infection 
and that inhibition of lactoperoxidase (with Dapsone) eliminates the anti-RSV effects of the Duox/LPO enhanced 
with KI.  Dapsone itself lacks anti-RSV activity (Supplemental Figure E5). 
 
 
Effect of KI on RSV replication and cytokines.  By immunohistochemistry, RSV viral antigen abundance was 
significantly reduced in epithelial cells lining both alveoli (Alv) and airways (bronchioles and bronchi, Br) in KI-
treated lambs compared to RSV-inoculated lambs with no KI treatment (Figures 3C, 3D, 3E).  Lambs receiving 
Dapsone, KI and RSV had significantly increased levels of RSV mRNA and antigen compared to control and KI-
treated lambs (no Dapsone) and also compared to M37 alone (no KI or Dapsone) (Fig. 3C, 3D).  Levels of RSV 
N gene mRNA, immune and inflammatory gene mRNAs were assessed by RT-qPCR.  RSV mRNA levels 
trended lower in KI-treated lambs but not significantly (supplemental Figure E3).  IL-8 mRNA levels were 
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significantly reduced in KI-treated lambs compared to RSV-inoculated lambs lacking KI (supplemental Figure 
E3).  Also, IFN mRNA levels were significantly higher in KI-treated lambs compared to lambs receiving RSV 
M37 without KI treatment (supplemental Figure E3).  Control lambs lacked RSV mRNA and increases/alterations 
in innate and adaptive immunity genes.  The levels of IFNβ, MCP-1α, MIP1α, RANTES, SBD-1, SP-A, TGFβ, 
and PD-L1 mRNA in KI-treated lambs trended higher compared to lambs inoculated with RSV M37 without KI 
prophylaxis.  In contrast, RNA levels of RSV and mRNA levels of CC10, IL-6, IL-10, IP10, MCP2, MIP1β, SP-D 
and TNFα trended higher for lambs receiving RSV M37 compared to RSV-inoculated lambs treated with KI.  (For 
more details on the RT-qPCR procedure, see online data supplement).  These findings demonstrate that KI 
treatment is associated with reductions in some parameters of RSV infection. 
 
Iodide effects on RSV M37 infection in 3-week-old lambs. 
 
It is possible that with increased lung maturation, the Duox or LPO enzymes or other components of the 
Duox/LPO/halide system undergo/exhibit increased expression and function compared to newborn lungs.  
Therefore, the extent to which KI treatment reduces RSV disease severity in 3-week-old lambs was determined. 
 
Effect of KI on clinical parameters, lesions, and bronchoalveolar lavage fluid.  Lung lesions were less frequent 
in 3-week-old lambs with KI treatment (8.6 ± 1.9) compared to RSV inoculated lambs lacking KI (4.9 ± 1.6) but 
this difference was not significant; control animals lacked lesions.  Consolidation scores determined by 
histopathology for 3-week-old lambs inoculated with RSV M37 and lacking KI treatment (1.1 ± 0.6) trended higher 
than those from lambs treated with KI (0.70 ± 0.7) but lacked statistical significance; controls (no RSV) lacked 
lesions (0.00 consolidation score).  Clinically, there were no significant differences in expiratory effort among 
control or treatment groups in 3-week-old lambs. There were no significant differences between groups of 3-
week-old lambs (RSV M37 without KI treatment; RSV M37 with KI treatment; control) in weight gain, temperature, 
heart and respiratory rates, and expiratory effort. To evaluate the effect of KI treatment on inflammatory cell 
populations within the lung, differential cell counts were performed on BALF.  In 3-week-old animals, KI treatment 
significantly reduced the proportion of macrophages within BALF in RSV-infected lambs.  No significant 
differences were detected in the populations of other cells, although there was a trend for the KI treated lambs 
to have a higher proportion of lymphocytes (p = 0.057) compared with RSV-infected lambs that did not receive 
treatment (Figure 4A).  Comparison between the two RSV-infected groups and uninfected controls were not 
possible in this age group since too few control lamb samples were present.   
 
Effect of KI on RSV replication.  RSV titers in BALF were significantly reduced in 3-week-old lambs treated with 
KI compared to lambs inoculated with RSV lacking KI (Figure 4B).  Control lambs (receiving no RSV or KI) lacked 
viral titers.  RSV viral antigen abundance determined by immunohistochemistry was significantly reduced in the 
epithelial cells lining both the airways (bronchi and bronchioles, Br) and alveoli (Alv) in 3-week-old lambs 
receiving KI compared to RSV-inoculated lambs lacking KI (Figure 4C).  The levels of RSV nucleoprotein mRNA 
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measured by RT-qPCR were significantly reduced in 3- week-old lambs receiving KI compared to RSV-
inoculated lambs lacking KI (Figure 4D).  
 
Ontologic expression of Duox 1, 2 and Lactoperoxidiase genes in lamb lung. 
Because the lung of newborns continues to develop and mature after birth and also because expression of 
Duox1, Duox2, and LPO is essential for converting I- into hypoiodous acid, the extent of expression of these 
genes during ontogeny was measured by RT-qPCR using total RNA isolated from lung tissues collected from 
lambs at various time points during gestation and compared to adult expression levels as described previously 
(41, 42).  Expression of lactoperoxidase and Duox1 was low preterm, at gestational days 115 and 130, and at 
birth, while expression was markedly increased in adults (Figure 5A and 5B).  Expression of Duox2 was 
increased at day 115 of gestation, decreased progressively with gestational age, and was also markedly 
increased in adults (Figure 5C).  These data indicate that Duox1, Duox2, and LPO are expressed in the airways 
of newborn lambs albeit at lower levels than in adult sheep.  
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DISCUSSION 
Viral respiratory tract infections are common and can be life threatening and there are no fully effective therapies 
or approved vaccines.  Overall our findings indicate that the use of high-dose KI supplementation in vivo lessens 
the severity of RSV infections in newborn and 3-week-old lambs, through the augmentation of mucosal oxidative 
defenses. 
 
There are several animal models of RSV infection and each has unique features.  Lambs, like infants, have 
submucosal glands which produce LPO and also express sufficient levels of Dual oxidases and halide transport 
systems (23, 24) to support formation of the pseudohypohalide OSCN- or, in the presence of sufficient I-, HOI.  
Rodents lack significant submucosal gland formation in the intrapulmonary airways and thereby also lack 
sufficient LPO production for a fully functional oxidative defense system within the airways (31).  In addition, 
lambs are susceptible to infection by several strains of RSV, including hRSV M37 used in this study (27, 28-30, 
33-36, 41).  Gerson et al. demonstrated that the ovine airway secretions contain LPO and that a reduction of 
LPO function by dapsone administration reduces antibacterial activity (23), thus demonstrating that the ovine 
airway has a functional LPO-dependent antibacterial system.  The present study further demonstrates that the 
ovine ASL contains SCN- and for the first time shows that intravenous (i.v.) or intragastric delivery of iodide 
increases ovine ASL [I-].  The results also suggest that the upper airway of lambs recapitulates the halide-
transporting activity of the human nasal mucosa.  Furthermore, the study is the first to show reductions in RSV 
disease severity following KI supplementation.  In addition to lacking significant submucosal glands, mice do not 
have NIS (sodium/iodide symporter) in the trachea (Banfi, unpublished observations) and thus would require 
enormous amounts of KI in order to reach the air surface liquid I- concentrations attained in lambs and humans 
receiving much less. 
 
Newborn lambs receiving KI exhibited reduced levels of expiratory effort, gross lesions, RSV antigen distribution, 
and a trend of reduced RSV N gene mRNA levels.  KI treatment in the older, 3-week-old lambs was associated 
with reduced RSV titers in BALF along with reduced RSV antigen load by immunohistochemistry, and reduced 
RSV nucleoprotein mRNA levels by RT-qPCR.  Microscopic lesions (consolidation scores) were not significantly 
reduced with KI treatment in either newborn or 3-week-old lambs, although there was a trend towards reduced 
lesions in the 3-week-old lambs.  Thus, while not all measured parameters of RSV infection were altered by KI 
treatment, reductions in viral parameters (e.g., viral titer, antigen, and RNA levels) and clinical features (reduced 
expiratory effort) are of particular significance in lessening RSV disease severity.  Mechanistically, administration 
of Dapsone with RSV and KI in newborn lambs reversed the effects of the KI treated and resulted in disease 
severity equal to and often significantly greater than M37 alone (no KI or Dapsone).  HOI and/or hypoiodite (OI-
) production is very difficult to measure in vivo because such reactive oxygen species have very short molecular 
half-lives in general (12, 14).  Thus, the extent to which HOI- was formed in the ASL of the KI-treated lambs in 
this study is not known.  However, because Dapsone inhibits lactoperoxidase (LPO) and LPO is essential for 
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catalyzing the reaction of KI and H2O2 to HOI, these findings suggest that:  1) the Duox/LPO system is 
essential to the anti-RSV activity seen in these studies and 2) KI itself is not sufficient for the anti-RSV activity.  
These findings are consistent with in vivo studies that demonstrated significant anti-RSV activity by HOI and a 
lack of direct RSV killing by KI, LPO, or H2O2 individually (24).  Dapsone has been used previously in sheep to 
inhibit LPO activity which allowed increased colonization by a Gram-negative bacterial pathogen in the 
respiratory tract (23).  Also, lambs in this study demonstrated high ASL [I-] levels when receiving daily KI.   It is 
also possible that there are other non-oxidative properties of KI that result in anti-RSV activity, such as its efficacy 
as an expectorant agent (43) but expectorants are generally not effective in reducing RSV replication. 
 
KI treatment reduced disease severity to a greater degree in 3-week-old lambs than in newborn lambs as 
reflected by the large reductions in titer, antigen, and viral mRNA levels (viral mRNA levels trended lower in KI-
treated 2-3 day old lambs were not significantly reduced despite a larger group number).  While the reason for 
this is not fully understood, we speculate that the respiratory tracts of 3-week-old lambs are more mature and 
have more fully differentiated epithelia than newborns and, therefore, have more available Duox/LPO expression 
and activity to convert KI to HOI than do newborn lambs.  Alternatively, we have shown previously that younger 
lambs (especially preterm) exhibit increased disease severity compared to older lambs.  Therefore, it could be 
that RSV disease severity was slightly less in the 3-week-old lambs as reflected by their lack of increased 
expiratory effort compared to the markedly enhanced expiratory efforts observed in the younger lambs.  Thus, if 
RSV disease severity is less in older lambs than newborn, the effects of KI treatment may appear more 
pronounced in older lambs.  It is also possible that older lambs may have enhanced innate and adaptive immune 
responses that synergize with KI treatment.   
 
KI was delivered prophylactically in this study and thus, iodide levels in the ASL were high at the time of RSV 
nebulization.  Because of this, it was suspected that nebulized particles would come into contact with HOI present 
on the ASL - inhibiting initial RSV attachment and infection.  However, while prophylactic administration of KI 
reduced many parameters of RSV infection and RSV disease severity, it did not completely prevent RSV 
infection; since KI-treated lambs developed some gross and histologic lesions, and viral RNA and antigen were 
present (albeit at significantly reduced levels) compared to untreated animals.  It is possible that not all RSV 
virions were inactivated upon initial contact with the respiratory mucosa during nebulization.  More specifically, 
it is likely that HOI levels are higher in the nasal mucosa, trachea and bronchi, all three of which are anatomical 
locations where submucosal glands (and LPO) are present, than in the distal bronchioles and alveoli (both 
lacking in submucosal glands).  Thus, nebulized virions deposited onto the upper airways may be 
damaged/destroyed by HOI whereas those virions deposited onto bronchioles or alveoli may have evaded HOI.  
Deposition and infection by RSV at these distal locations may allow some level of viral infection since the distal 
bronchioles and alveoli are important sites of RSV replication.  In other words, there may be a mismatch between 
sites of HOI production and some areas of the airways and alveoli that are susceptible to RSV infection.   
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Because KI was delivered daily after initial infection, it is also possible that HOI has effects on RSV virions 
produced in the lung after RSV nebulization.  KI treatment may impair/damage virus released from respiratory 
mucosa during replication cycles several days after inoculation of RSV.  Prophylactic protection by KI, as 
demonstrated in this study, might be effective in preventing spread of RSV to non-infected individuals treated 
with KI.  It is also possible that KI treatment might have some beneficial effect in individuals already infected with 
RSV.  Further studies are needed to optimize KI as a therapeutic, including determining its effectiveness with 
different routes of infection (intratracheal, intrabronchial, or aerosolized RSV), activity against different viral and 
bacterial pathogens, optimizing the dose and timing of KI administration, and the effects of inhibition of various 
components of the Duox/LPO/halide system. 
 
In a previous study, we showed that the [I-] increased in the upper airway secretions of human subjects following 
oral intake of KI (24).  In the current study, through the use of the lamb model, we determined that I- was secreted 
not only in the upper airways, but also in the trachea following I- supplementation.  In both humans and lambs, 
the [I-] was found to be more than 20-fold higher in ASL than in serum.  The mechanism responsible for secretion 
of I- in the airways is not known.  Fragoso and colleagues have reported that the sodium-iodide symporter (NIS) 
is expressed in the submucosal glands of airways where it is localized to the basolateral membrane of epithelial 
cells (16).  On the apical side of the epithelium, I- may be exported through I- permeable ion channels or anion 
transporters.  Among the apical anion channels of airway epithelia, Ca2+-activated Cl- channels and the cystic 
fibrosis transmembrane conductance regulator (CFTR) are known to be I- permeable (44).  Furthermore, the 
anion transporter, pendrin, has been detected in the apical membrane of airway epithelial cells (20).  NIS, CFTR, 
Ca2+-activated Cl- channels, and pendrin have also been implicated in the secretion of SCN-.  The fact that the 
increased ASL [I-] is accompanied by reduced SCN- levels supports the notion that the same ion transporters 
are involved in both SCN- and I- secretion in the airways.  
 
Previous studies have shown that lambs express all components of this mucosal oxidative defense system at 
levels sufficient for activity in the airways (23), and our results indicate that prophylactic administration of KI 
reduces RSV disease severity.  These findings have implications for use of KI in infants against RSV or other 
respiratory pathogens since KI is relatively inexpensive, stable, can be readily transported, and does not require 
refrigeration or specialized storage.  The extent to which KI treatment may reduce RSV disease severity in 
preterm and premature lambs and in lambs was not assessed in this study.  RSV disease in humans often occurs 
in infants born prematurely and therapies are needed, but additional studies will be required in order to better 
understand the ontogeny and activity of the components of the Duox/LPO/halide host defense system in the 
preterm lung.  Overall our findings indicate that the use of high-dose KI supplementation in vivo lessens the 
severity of RSV infections, potentially through the augmentation of mucosal oxidative defenses. 
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Figure legends 
Figure 1. I- concentrations in the airway secretions and serum of lambs following systemic 
administration of I-. (A) I- concentration in nasal secretions of lambs at the indicated time points 
following intravenous (i.v.) injection of NaI (filled circles, n = 5) or PBS (open circles, n = 5) at 0 
hour. (B) I- concentrations in the serum of lambs at the indicated time points following i.v. 
administration of NaI (filled triangles, n = 5) or PBS (open triangles, n = 5) at 0 hour. (C) I- 
concentration in the nasal and tracheobronchial secretions of lambs (filled circles and squares, 
respectively) at the indicated time points following intragastric (i.g.) KI administration at 0 hour.  
The number of animals used for the collection of nasal secretions was 5 (0 h and 4 h), 4 (12 h), 
and 3 (36 h). The number of animals used for the collection of tracheal secretions was 1 (4 h), 1 
(12 h), and 3 (36 h).  (D) I- concentration in the serum of lambs (n ≥ 3) at the indicated time points 
following i.g. delivery of KI. Error bars = SEM. 
 
Figure 2. Effect of oral KI supplementation on hRSV A2 mRNA levels and ASL [I-]. (A) RSV 
replication and (B) [I-] in tracheal ASL were evaluated 6 days after inoculating lambs with hRSV 
A2; the indicated groups of animals also received daily doses of KI (1.8 mg/kg BW). (A) RSV 
mRNA signal normalized to total RNA loaded per RT-qPCR:  Control n = 5; RSV+KI n = 5; RSV 
n = 5. (B) No KI n = 5; KI n = 5. Error bars = SEM, *p<0.05. 
 
Figure 3. The effect of KI on RSV M37 infection newborn (2-3 day old) lambs.  (A)  Enhanced 
expiratory effort (forced expiration).  Lambs inoculated with RSV M37 and receiving KI had 
significantly reduced expiratory efforts at days 3, 4 and 5 post-inoculation compared to RSV-
inoculated lambs lacking KI and control lambs. Control group n = 6; M37 group n = 11; M37+KI 
group n = 10. Error bars = SEM, *p<0.05, ***p<0.001. (B)  Lambs receiving KI had significantly 
reduced gross lesions compared to RSV-inoculated lambs lacking KI and control lambs.  RSV 
M37 infected lambs receiving KI and Dapsone had significantly increased gross lesions compared 
to control and RSV-infected (no KI).  Control group n = 14; M37 group n = 11; M37+KI group n = 
10; M37 + KI + Dapsone (n = 5).  Error bars = SEM, *p<0.05, ***p<0.001.  The minor control group 
lesions were found (by immunohistochemistry) to not be RSV.  (C)  Lambs receiving KI had a 
trend of reduced RSV M37 mRNA compared to lambs lacking KI whereas lambs receiving RSV 
M37, KI and Dapsone had significantly increased RSV M37 mRNA levels compared to M37 alone 
and M37 + KI.  Error bars = SEM, *p<0.05, ***p<0.001.  (D)  Newborn lambs inoculated with RSV 
M37 and receiving KI had significantly reduced levels of viral antigen in alveolar regions compared 
to RSV-inoculated lambs lacking KI. In bronchioles, RSV M37 antigen was not significantly 
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altered; control lambs lacked RSV antigen.  RSV M37-infected lambs receiving KI and Dapsone 
had significantly increased RSV antigen compared to control and RSV-infected (no KI).  Control 
group n = 14; M37 group n = 11; M37+KI group n = 10; M37 + KI + Dapsone (n = 5).  Error bars 
= SEM, *p<0.05, ***p<0.001   (E, F).  Lung, newborn lambs infected with RSV M37 and stained 
for RSV antigen.  (E)  Lung of lamb lacking KI administration in which there is abundant RSV 
antigen (brown) in most airway epithelial cells.  (F)  Lung of lamb that received KI; a few cells 
contain RSV antigen. 
 
Figure 4.  The effect of KI on RSV M37 infection in 3-week old lambs.  (A)  Effect of KI treatment 
on the cellular composition of BALF in RSV-infected 3-week-old lambs. Cytospin preparations of 
BALF were stained with modified Wright’s, and 300 cell differentials were performed to assess 
relative differences in populations of inflammatory cells.  Values are expressed as mean ± SD, 
*p<0.01 based on ANOVA followed by Tukey-Kramer multiple comparisons test.  (B)  
Bronchoalveolar lavage fluid (BALF) titers of RSV in 3-week-old lambs. Lambs receiving KI had 
significantly less viable RSV than lambs lacking KI. Control lambs lacked RSV titers. Control 
group n = 4; M37 group n = 5; M37+KI group n = 5. Error bars = SEM, *p<0.05.  (C)  RSV M37 
mRNA levels in lungs of lambs receiving KI trended toward significant reductions compared to 
RSV-inoculated lambs lacking KI; controls lack RSV mRNA.  Control group n = 8; M37 group n = 
10; M37+KI group n = 10. Error bars = SEM, *p<0.05, **p<0.001.  (D)  3-week-old lambs receiving 
KI had significantly reduced levels of RSV antigen in both bronchiolar and alveolar regions 
compared to RSV-inoculated lambs lacking KI; controls lacked RSV antigen. Control Br n = 8; 
Control Alv n = 8; M37 Br n = 30; M37 Alv n = 30; M37+KI Br n = 30; M37+KI Alv n = 30. Error 
bars = SEM, *p<0.05, **p<0.01.   
 
Figure 5.  Ontogeny of lung expression of lactoperoxidase (LPO) and dual functioning oxidases 
1, 2 (Duox1 and Duox2) in lambs as assessed by RT-qPCR.  (A) Expression of LPO mRNA at 
various stages throughout lamb development. 115 day (of gestation) group n = 5; 130 day (of 
gestation) group n = 4; Term lamb group n = 4; Adult lamb group n = 4. Error bars = SEM, *p < 
0.05.  (B) Expression of Duox1 mRNA at various stages throughout lamb development.  (C) 
Expression of Duox2 mRNA at various stages throughout lamb development.  115 day group n = 
3; 130 day group n = 3; Term lamb group n = 4; Adult lamb group n = 4. Error bars = SEM, *p < 
0.05. 
 
This is a manuscript of an article from American Journal of Respiratory Cell and Molecular Biology 50 (2014): 389,  doi: 
10.1165/rcmb.2012.0529OC. Posted with permission. 
 
 
Fig. 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I-
in
 s
er
um
 (µ
M
)
Time (hours)
Time (hours)
I-
in
 a
irw
ay
 s
ec
re
tio
ns
 (µ
M
)
Time (hours)
I-
in
 n
as
al
 s
ec
re
tio
n 
(µ
M
)
A
C
B
D
0 10 20 30 40
0
100
200
300
400
 NaI (i.v.)
 PBS (i.v.)
 
 
0 10 20 30 40
0
4
8
12
16
 
 
 NaI (i.v.)
 PBS (i.v.)
I-
in
 s
er
um
 (µ
M
)
Time (hours)
0 10 20 30 40
0
4
8
12
16
 KI (i.g.)
 
 
0 10 20 30 40
0
100
200
300
400
 
 
 nasal secretion (KI i.g.)
 tracheobronchial secretion (KI i.g.)
  
23
 
Fig. 2. 
 
A                                                                                      B 
Control hRSV A2 + KI hRSV A2
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
I-  
in
 A
SL
 ( 
M
)
No KI KI
0
50
100
150
200
250
300
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
24
 
Fig. 3.         
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Fig. 4. 
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Fig. 5. 
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Table 1.  RT-qPCR primers and hydrolysis probes used in this study. 
             Primer name                                Sequence (5’→3’)                                                   Accession # or source 
RSV M37 Forward  
 RSV M37 Reverse  
 RSV M37 Probe 
GCTCTTAGCAAAGTCAAGTTGAA[C]GA 
TGCTCCGTTGGATGGTGTATT 
6FAM-ACACTCAACAAAGATCAACTTCTGTCATCCAGC 
M11486 and Meridian LifeScience literature; 
nucleoprotein sequence.  [ ] = T for hRSV A2 
forward primer 
CC-10 Forward  
 CC-10 Reverse  
 CC-10 Probe 
GCTGCCCTGGAACCTTTCA 
CCTTCAGCTGTCTTGTTGCTTCT 
6FAM-CCCTGACGAAGACATG-MGBNFQ 
Cloned and sequenced in our lab 
by Dr. Albert van Geelen, 2008 
IFN Forward  
 IFN Reverse 
 IFN Probe 
TGGTTCTCCTGCTGTGTTTCTC  
CGTTGTTGGAATCGAAGCAA  
6FAM-ACCACAGCTCTTTCCAGGAGCTACA-TAMRA 
NM_174350 
IFN Forward  
 IFN Reverse 
 IFN Probe 
TGGAGGACTTCAAAAGGCTGAT  
GATGGCTTTGCGCTGGAT  
6FAM-CAAATTCCGGTGGATGATCTGC-TAMRA 
NM_001009803 
IL-6 Forward  
 IL-6 Reverse  
 IL-6 Probe 
GCTGCTCCTGGTGATGACTTC  
GGTGGTGTCATTTTTGAAATCTTCT  
6FAM-CTTTCCCTACCCCGGGTCCCCTG-MBGNFQ 
NM_001009392 
IL-8 Forward  
 IL-8 Reverse  
 IL-8 Probe 
TTCCAAGCTGGCTGTTGCT  
TTGACAGAACTGCAGCTTCACA  
6FAM-CCGCTTTCCTGCTCTCTGCAGCTC-TAMRA 
X78306 
IL-10 Forward  
 IL-10 Reverse  
 IL-10 Probe 
GTCGGAAATGATCCAGTTTTACCT  
GTCAGGCCCATGGTTCTCA  
6FAM-AGGAGGTGATGCCACAGG-MGBNFQ 
Z29362 
IP10 Forward  
 IP10 Reverse  
 IP10 Probe 
CACCCTGAGCTGTTCAGTAGTGA 
GCGCCCCGGTATAGCTTAC 
6FAM-CCCTGGCACTGTGAC-MGBNFQ 
NM_001009191 
MCP-1 Forward  
 MCP-1 Reverse  
 MCP-1 Probe 
GCTGTGATTTTCAAGACCATCCT  
GGCGTCCTGGACCCATTT  
6FAM-AAAGAGTTTTGTGCAGACCCCAACC-TAMRA 
†Vet Immunol Immunopathol 
 2001;82:153–64. 
MCP2 Forward 
 MCP2 Reverse 
 MCP2 Probe 
GCTCGCTCAGCCAGATTCAG 
CTTCCCATTGGTCACACTAAAGC 
6FAM-TTCTATCCCAATCACCTGC-MGBNFQ 
†Vet Immunol Immunopathol 
 2001;82:153–64. 
MIP1 Forward  
 MIP1 Reverse  
 MIP1 Probe 
GGCCTGCTGCTTCTCCTATG 
TGGTCTCAAAATAGTCAGCTACGATT 
6FAM-CGCCCGGCAGCTTTCTCGC-TAMRA 
NM_174511 
MIP1 Forward  
 MIP1 Reverse  
 MIP1 Probe 
GCGCCAACCCCAGTGA 
CAGCTCAGTTCAATTCAAGGTCAT 
6FAM-TGGGTCCAGGAGTACG-MGBNFQ 
EU366479 and NM_001075147 XM_582039 
RANTES Forward  
 RANTES Reverse  
 RANTES Probe 
TGCTTCTGCCTCCCCATATG  
GGGCGGGAGATATAGGCAAA  
6FAM-CACCACGCCCTGCT-MGBNFQ 
Based on alignment of human  
 (NM_002985) and bovine (NM_175827) 
sequences 
SBD-1 Forward  
 SBD-1 Reverse  
 SBD-1 Probe 
CCATAGGAATAAAGGCGTCTGTGT  
CGCGACAGGTGCCAATCT  
6FAM-CCGAGCAGGTGCCCTAGACACATGA-TAMRA 
U75250 
SP-A Forward  
 SP-A Reverse  
 SP-A Probe 
TGACCCTTATGCTCCTCTGGAT  
GGGCTTCCAAGACAAACTTCCT  
6FAM-TGGCTTCTGGCCTCGAGTGCG-TAMRA 
AF076633 
SP-D Forward  
 SP-D Reverse  
 SP-D Probe 
ACGTTCTGCAGCTGAGAAT  
TCGGTCATGCTCAGGAAAGC  
6FAM-TTGACTCAGCTGGCCACAGCCCAGAACA-
TAMRA 
AJ133002 
TGF Forward  
 TGF Reverse 
 TGF Probe 
TGTGTTCGTCAGCTCTACATTGAC  
TAGCCCTTGGGTTCGTGAAT  
6FAM-TCCAGCCCAGGTCCTTCCGGA-TAMRA 
NM_001009400 
TNF Forward  
 TNF Reverse 
 TNF Probe 
CAACCTGGGACACCCAGAAT  
TCTCAAGGAACGTTGCGAAGT  
6FAM-CAAGGGCCAGGGTTCTTACCGGAA-TAMRA 
NM_001024860 
PD-L1 Forward  
 PD-L1 Reverse  
 PD-L1 Probe 
TGGTCATCCCAGAACCATATCTAG 
CCCAGAGTCACCAAGTGATTCC 
6FAM-TCCAGCAAAAAAG-MGBNFQ 
XM_613366 
 
 
 
 
 
 
Table 1 Footnotes:  †For MCP-1 and MCP2 sequences. Dunphy J, Horvath A, Barcham G, 
Balic A, Bischof R, Meeusen E. Isolation, characterization and expression of mRNAs encoding 
the ovine CC chemokines, monocyte chemoattractant protein (MCP)-1alpha and -2. Vet 
Immunol Immunopathol 2001;82:153-164. 
  
MATERIALS AND METHODS 
Lamb RSV challenge experiments (methods continued from text).  
In the 2-3 day old lambs and 3-week-old lambs, each of the 3 groups of lambs contained 6 
animals, and the experiment was carried out twice in 2-3 day-old (newborn) lambs (n = 12 in each 
treatment group) and once in an additional group (n = 5 lambs) that received daily administration 
of 2.014 mM Dapsone (Sigma-Aldrich; 4-aminophenyl sulfone in 3 mL sterile 0.9% saline 
containing 1 % w/v ethanol and 0.1% w/v DMSO  nebulized to completion with a PARI nebulizer 
(13 minutes) along with RSV and KI.  Dapsone inhibits lactoperoxidase and thereby reduces 
conversion of H2O2 and I- to OI-.  Also, the design was used once in 3-week-old lambs (n = 6 in 
each treatment group).  Both RSV strains were grown in HEp-2 cells.  After inoculation of RSV, 
lambs in all groups received daily antibiotics (Ceftiofur, 1-2 mg/kg body weight, intramuscular) to 
prevent secondary bacterial infections.  The animals’ temperature, weight, and respiratory rates, 
and clinical severity of RSV disease for each lamb was assessed daily and scored as described 
(28, 33-36); increased expiratory effort (also termed forced expiration) was scored blindly daily 
as:  0 = no increased effort; 1 = earliest detectable; 2 = moderate (>1 sec) with some abdominal 
effort; 3 = marked (>3 sec) with hard abdominal effort.  Lambs were euthanized by sodium 
pentobarbital overdose on day 6 post-inoculation when RSV-induced lesions are maximal in this 
model (28, 33-36).  During the RSV challenge experiments, lambs received a custom diet (Milk 
Products Inc., Chilton, WI, USA) that lacked supplemental I- and the lack of I- in this diet was 
verified in our laboratory using anion-exchange chromatography as previously described (24, 32).  
All animal experiments were approved by the Institutional Animal Care and Use Committee 
(IACUC) of Iowa State University.  
 
Post-mortem analysis of RSV disease severity. 
The thoraxes of euthanized lambs were opened, lungs photographed in situ and ex vivo, and 
gross lesions were scored as described previously (28, 33-36).  Multiple samples from each lung 
lobe were collected and processed for RNA isolation as described previously (28, 33-41).  The 
isolated RNA was assessed for quality (supplemental figure E1) and used for RT-qPCR analysis 
of the expressions of RSV nucleoprotein (N gene) mRNA, immune and inflammatory gene 
 
 
 
mRNAs according to the PREXCEL-Q Method (30-33, see protocol, below).  Primers and probes 
were designed using ABI Primer Express 2.0 (see oligo sequences in supplemental Table 1).  
Two additional samples from each lobe were fixed in 10% neutral-buffered formalin, embedded 
into paraffin, sectioned, stained with H & E, and assessed by light microscopy for lung lesions as 
described previously (28, 33-36).  Briefly, a 4-point scale was used to describe the percentage 
involvement of lung parenchyma: 0% consolidation = 0, 1-9% consolidation = 1, 10-39% 
consolidation = 2, 40-69% consolidation = 3, 70-100% consolidation = 4.  Other formalin-fixed 
paraffin-embedded (FFPE) sections of the lung lobes were used for the immunohistochemical 
detection of RSV antigen expression, and the expression of RSV antigen was scored as described 
previously (25, 30-33, see more details below).  
 
In addition to the lung collected for RNA isolation and histological samples, bronchoalveolar 
lavage fluid (BALF) was also collected from each 3-week-old lamb and used for the determination 
of viral titers and cytology (see details in the online data supplement).  Briefly, the right caudal 
lung lobe was flushed through a major bronchus with 5 ml of cold modified Iscove's media 
(containing 42.5% Iscove's modified Dulbecco's medium, 7.5% glycerol, 1% heat-inactivated 
FBS, 49% DMEM, and 5 µg/ml kanamycin sulfate), and 1 ml of the collected BALF was used for 
infectious focus assay (see detailed protocol in the online data supplement).  BALF was also 
collected from the accessory lobe by flushing the lobe through its major bronchus with 1 ml sterile 
PBS.  These BALF samples were analyzed for total nucleated cell count and differential cell count 
by a board certified veterinary clinical pathologist blinded to the identity of individual samples (see 
details of the cytology method in the online data supplement).  In some BALF samples, too few 
intact nucleated cells were present to perform a differential cell count; these samples were 
excluded from the statistical analysis. 
 
Effect of Dapsone on RSV in vitro 
The extent to which dapsone may have anti-RSV activity was assessed in vitro. HEp-2 cells were 
grown to 90% confluence in 12-well culture plates in MEM media supplemented with 10% FBS 
and 1% pen/strep.  5*103 FFU of RSV-GFP was mixed with increasing concentrations of Dapsone 
solution (Sigma-Aldrich; 4-aminophenul sulfone in sterile 0.9% saline containing 1% w/v ethanol 
and 0.1% w/v DMSO) with a final volume of 300 μl.  For controls, RSV-GFP (recombinant 
replication competent RSV-A2 strain expressing GFP) (E8) was added to either the diluent alone 
or serum free MEM.  The final concentration of ethanol and DMSO for the Dapsone treated virus 
and diluent control was 0.97% and 0.097% respectively.  The samples were incubated together 
 
 
 
at 37˚C and 5% CO2 for 2 hours.  The RSV-Dapsone mixture was then added to HEp-2 cells and 
incubated for 2 hours at 37˚C and 5% CO2.  The remaining virus was then washed off with 1X 
PBS and fresh media applied.  Following overnight incubation, green fluorescent foci were 
counted for 5 random fields per well using the GFP filter on an inverted stage fluorescence 
microscope (Olympus IX70, Center Valley, PA, USA). 
 
Ontologic expression of Duox1, Duox2, and LPO genes in lamb lung. 
The extent to which Duox1, Duox2, and LPO mRNA are expressed in the lung during development 
was assessed by RT-qPCR using lung RNA from lambs at various developmental time points:  
115 days gestation (n = 5), 130 days gestation (n = 4), at birth (n =4) and adults (n = 4) as 
described previously (41, 42).   
 
Infectious focus assay used on collected BALF samples.   
BALF was collected as described above, and 1 ml samples from each lamb were tested for the 
presence of live virus by an infectious focus assay.  Briefly, HEp-2 cells were grown to 70% 
confluence in 12-well culture plates (Fisher Scientific, Hanover, IL, USA) in DMEM media 
(Mediatech, Inc., Manassas, VA, USA) supplemented to 10% with heat-inactivated fetal bovine 
serum (FBS) (Atlanta Biologicals, Atlanta, GA, USA) and 50 g/ml kanamycin sulfate (Invitrogen).  
Each sample was analyzed at full-strength and at four additional serial-dilutions of 10-fold, 100-
fold, 1,000-fold and 10,000-fold.  200 l of each BALF sample dilution was added in duplicate to 
wells of a 12-well plate (e.g., each BALF sample used an entire 12-well culture plate); two control 
wells on each plate received virus-free cell culture medium.  Plates were incubated for 80 minutes 
in a CO2 incubator at 37°C and 5% CO2 with manual rocking every 20 minutes.  1 ml of culture 
medium was added to each well and plates were allowed to incubate for 48 hours after which 
medium was removed from all wells and cells in all wells were immediately fixed with 60% 
acetone/40% methanol solution for 1 minute.  The acetone/methanol was removed and plates 
were allowed to air dry for about 2 minutes after which each well was rehydrated with 1 ml TBS-
0.05% Tween 20, pH 7.4-7.6 (TBS-tw) for 1 minute with mild rotation.  To block non-specific 
binding, 1 ml of 3% BSA (Fisher Scientific) in TBS-tw was added to all wells at room temperature 
for 30 minutes with gentle rocking.  Primary antibody (MAb to RSV Fusion Protein, Clone: RSV 
3216 (B016), Meridian Bioscience, Cincinnati, OH, USA) was diluted 1:800 in TBS-tw containing 
3% BSA; 325l of this was added to each well and plates were allowed to incubate overnight at 
4°C with gentle rocking.  In the morning, plates were washed gently three times for 5 minutes 
each with TBS-tw, then 325l secondary antibody (Goat anti-Mouse Fab’ conjugated to 
 
 
 
AlexaFluor 488, Invitrogen) diluted 1:800 in TBS-tw containing 3% BSA was added to each well 
and allowed to incubate at room temperature for 30 minutes with gentle orbital rotation.  Plates 
were rinsed two times for 5 minutes each with TBS-tw and 1 ml of TBS-tw was added back to 
each well prior to microscopic inspection.  Plates were inspected for the presence of fluorescent 
foci of infection using the FITC/GFP filter on an inverted stage fluorescence microscope (Olympus 
CKX41, Center Valley, PA, USA).  Clusters of 5 or more fluorescing cells were counted as single 
infectious focal events.  Results were calculated according to the following equation:  an average 
of 100 counts in a 1:10-diluted (duplicate) sample would indicate that the original BAL sample had 
a “titer” of 5000 since [100 counts x dilution of 10 x 1000 l/ml]/200 l assessed = 5000 infectious 
foci/ml. 
 
Reverse transcription polymerase chain reaction (RT-qPCR) measurement of levels of:  RSV and 
immune and inflammatory gene mRNA.  
Tissues from the right and left cranial, right and left middle, and right and left caudal lung lobes 
(0.3 - 0.4 g of each) were homogenized in TRIzol (Invitrogen, Carlsbad, CA, USA), pooled in equal 
portions to create a composite slurry for each animal, then adjusted to 0.091 g/ml with additional 
TRIzol.  RNA isolation continued as per manufacturer’s instructions (Invitrogen), followed by 
DNase treatment (Ambion, TURBO DNase, Austin, TX, USA) and 10-fold dilution with a 
combination of RNaseOUT (Invitrogen) and ultrapure water (Millipore).  A NanoDrop (NanoDrop-
1000, Thermo Scientific, Waltham, MA, USA) was used to assess each sample for simple RNA 
purity and total RNA quantity (A260nm/A280nm all >1.95).  Agilent Bioanalyzer 2100 (Agilent 
Technologies, Santa Clara, CA, USA) analysis of total RNA prior to DNase treatment and dilution 
routinely showed RIN values of 8.0 or higher (Figure E1).  RT-qPCR was carried out using One-
Step Fast qRT-PCR Kit master mix (Quanta, BioScience, Gaithersburg, MD, USA) in a GeneAmp 
5700 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA) employing 
PREXCEL-Q for all set up calculations (E1-E5).  The following targets were assessed:  RSV M37 
nucleoprotein mRNA (M37), Clara cell secretory protein (CC10), surfactant protein A (SP-A), 
interleukin 8 (IL-8), interleukin 10 (IL-10), macrophage inflammatory protein (MIP1α), monocyte 
chemotactic protein (MCP1α), tumor necrosis factor alpha (TNFα), interferon beta (IFNβ), 
interferon gamma (IFNγ), and regulated on activation normal T-cell expressed and secreted 
(RANTES).  Thermocycling conditions were 3 minutes at 50°C, 30 seconds at 95°C followed by 
45 cycles of: 3 seconds 95°C and 30 seconds at 60°C.  Each 10-fold diluted total RNA sample 
was further diluted so that each final RT-qPCR contained 0.784 ng RNA/µl (determined to be 
optimal by PREXCEL-Q).  Each sample and standard was assessed in duplicate and each target 
 
 
 
gene quantification cycle (Cq) value converted to a relative quantity (rQ) based on the 
corresponding standard curve using the following equation:  rQ = 10((Cq-b)/m), where b and m are 
the y-intercept and slope, respectively, from the Stock I-derived standard curve for each target 
(E1, E2).  The efficiency-corrected delta Cq (EAMPCq) method was employed for RT-qPCR 
quantification analysis.  Results were normalized to total lung RNA loaded per RT-qPCR; which 
was identical for all reactions.  No-RT control qPCR reactions (NRC) consistently gave either no 
signal, or generated Cq values >13 cycles away from the RT-qPCR target reactions.  Inhibition 
was absent from all reactions as determined by the PREXCEL-Q method. 
 
Immunohistochemistry:   
Immunohistochemistry for detection, localization, and quantification of RSV antigen was 
performed on paraffin-embedded tissue as described previously (E5, E6), with the following 
variations: instead of Pronase E antigen retrieval, heated buffer antigen retrieval was performed 
in TE-0.05% Tween 20, pH 9.0 in a pressure cooking device (Decloaking Chamber™ Plus, 
Biocare Medical, Concord, CA) using the factory default program which lasted about 40 minutes, 
during which time the peak temperature of 125°C was reached in about 18 minutes, and after 
which the system cooled down to 80°C in another 22 minutes.  Blocking for 15 minutes with 3% 
bovine serum albumin (BSA) (Fisher Scientific) in TBS-0.05% Tween 20, pH 7.4 (TBS-tw) was 
followed by blocking with 20% normal swine serum (NSS) (Gibco/Invitrogen) in TBS-tw for 15 
minutes.  Primary polyclonal goat anti-RSV (all antigens) antibody (EMD/Millipore/Chemicon, 
Billerica, MA) was applied for 1.5 hours at room temperature (~22°C) at a dilution of 1:500 (~8 
g/ml) in TBS-tw containing 10% NSS and 3% BSA.  After rinsing with TBS-tw, 1:300-diluted 
biotinylated rabbit anti-goat secondary antibody (Kirkegaard-Perry Labs, Gaithersburg, MD) in 
TBS-tw containing 10% NSS and 3% BSA was applied for 45 minutes, slides were rinsed, blocked 
with 3% peroxide in TBS-tw for 25 minutes, and streptavidin-conjugated HRP (Invitrogen) diluted 
1:200 in TBS-tw was applied for 30 minutes.  After rinsing the slides, color was developed using 
Nova Red (Vector, Burlingame, CA, USA) for about 1.5 minutes followed by water rinses, 
counterstaining with Harris’ hematoxylin, bluing with alkaline Scott’s water, dehydration and 
cover-slipping.  Slides (containing two pieces of lung tissue each) were scored by the following 
method:  20 unique 10X fields on each slide were assessed for antigen staining and 
immunoreactive cells were counted within bronchioles and alveoli.  The number of cells 
immunoreactive for RSV per field was then given a score according to the following scale:  0 = 0, 
1 = 1-10 immunoreactive cells, 2 = 11-39 immunoreactive cells, 3 = 40-99 immunoreactive cells, 
4 = >100 imunoreactive cells. 
 
 
 
 
Bronchoalveolar lavage fluid (BALF) cytology.   
Aliquots of BALF (obtained from each lamb by pipetting 1 ml sterile PBS, pH 7.4 into the major 
bronchus of the accessory lobe and recovering 500 l of fluid) were submitted to the clinical 
pathology laboratory (Iowa State University, College of Veterinary Medicine) for measurement of 
total nucleated cell count and cytology slide preparation.  Cell counts were performed on a ADVIA 
120™ automated hematology analyzer (samples were diluted 2-fold in isotonic saline prior to cell 
counts due to low sample volumes).  Cytospin preparations of BALF were created using a 
Shandon Cytospin 3 set at 800 rpm (spun for 10 minutes with low acceleration).  Slides were 
stained with modified Wright’s using a Hematek automated stainer.  Differential cell counts (based 
on a 300 cell differential) were performed by a board certified veterinary clinical pathologist 
blinded to the identity of individual samples.  In some BALF samples, too few intact nucleated 
cells were present on the cytospin samples to perform a 300 cell differential; therefore, these 
samples were excluded from the final analysis. 
 
Statistical Analysis.   
All analyses were performed using GraphPad Prism 6 (GraphPad Software Inc, La Jolla, CA).  All 
post-mortem data was assessed by one-way ANOVA followed by Tukey’s post-test.  All clinical 
data were assessed by two-way ANOVA, and cumulative weight change was additionally 
assessed by one-way ANOVA followed by Tukey’s post-test. 
  
 
 
 
 
 
 
Figure E1. Typical RIN values obtained for RNA used for RT-qPCR in this study. Bioanalyzer 
2100 assessments for RNA integrity number (RIN) demonstrating high quality TRIzol-isolated 
total lamb lung RNA samples prior to use in RT-qPCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure E2. SCN- concentration in the nasal secretions of lambs declines temporarily following 
the i.v. injection of NaI (filled squares, n = 5). In contrast, i.v. injection of PBS does not affect the 
SCN- concentration in the nasal secretions (open squares, n = 5). *p<0.05, unpaired t test. 
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Figure E3.  Effect of KI on mRNA levels of immune and inflammatory genes six days following 
initial virus inoculation in 2 to 3-day-old lambs. Messenger RNA levels of interleukin-8 (IL-8) were 
significantly increased in lambs inoculated with RSV M37 compared to KI-treated lambs; whereas 
mRNA levels of IFN were increased significantly in KI-treated lambs compared to lambs receiving 
RSV M37 without KI treatment. Control lambs lacked increases/alterations in innate and adaptive 
immune genes. Messenger RNA levels in KI-treated lambs for IFNβ, MCP-1α, MIP1α, RANTES, 
SBD-1, SP-A, TGFβ, and PD-L1 trended higher compared to lambs inoculated with RSV M37 but 
lacking KI. In contrast, levels of CC10, IL-6, IL-10, IP10, MCP2, MIP1β, SP-D, and TNFα mRNA 
trended higher in lambs receiving RSV M37 compared to RSV-inoculated lambs treated with KI. 
Control group n = 10; M37 group n = 16; M37+KI group n = 14. Error bars = SEM, *p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure E4.  Effect of KI on mRNA levels of immune and inflammatory genes six days following 
initial virus inoculation in 3-week-old lambs.  Messenger RNA levels of IFN, IL-8 and RANTES 
were reduced (IFN significantly) by KI treatment; whereas IL-10, TGFβ, and MIP1α were 
significantly increased.  Control group n = 4; M37 group n = 5; M37+KI group n = 5. Error bars = 
SEM, ***p<0.001, **p<0.01, *p<0.05. 
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Figure E5.  Effects of Dapsone or diluent on RSV-A2 infectivity in vitro.  Neither Dapsone nor the 
diluent (1% w/v Ethanol, 0.1% DMSO, in 0.9% sterile saline) affected RSV infectivity of HEp-2 
cells (no significant differences).  For the media control RSV-A2 was diluted in serum free MEM.  
The experiment was replicated 4 times.  Values shown represent mean ± SE.   
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